Vaccine. 2010 Sep 14;28(40):6573-80. Epub 2010 Aug 4.

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.

Genton B, D'Acremont V, Lurati-Ruiz F, Verhage D, Audran R, Hermsen C, Wolters L, Reymond C, Spertini F, Sauerwein R.

Source

Department of Ambulatory Care and Community Medicine, University of Lausanne, Switzerland. Blaise.genton@hospvd.ch

Abstract

The aim of this Phase I/IIa double-blind controlled trial was to test the efficacy of the sporozoite-based malaria vaccine PfCS 282-383 (PfCS102) to protect against Plasmodium falciparum parasitaemia. 16 volunteers were randomized to receive twice 30 μg of PfCS102 formulated in Montanide ISA 720 or ISA 720 alone (control). Two weeks after 2nd immunization, volunteers were challenged using 5 infected mosquitoes. All vaccinees developed antibodies against PfCS102 versus none control. 8/8 vaccinees and 6/6 controls challenged developed malaria parasitaemia. The duration from infection to onset of patent parasitaemia was similar in both groups (214 h in vaccinees and 216 in controls). PfCS102 is safe and immunogenic but provides no protection against artificial challenge in its current formulation.

PMID:: 20691266; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Supplemental Content

Save items

Related citations in PubMed

The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial. [PLoS One. 2009]
The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.
Audran R, Lurati-Ruiz F, Genton B, Blythman HE, Ofori-Anyinam O, Reymond C, Corradin G, Spertini F. PLoS One. 2009 Oct 2; 4(10):e7304. Epub 2009 Oct 2.
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. [Vaccine. 2010]
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, et al. Vaccine. 2010 Jul 12; 28(31):5135-44. Epub 2009 Sep 6.
Protection against a malaria challenge by sporozoite inoculation. [N Engl J Med. 2009]
Protection against a malaria challenge by sporozoite inoculation.
Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, et al. N Engl J Med. 2009 Jul 30; 361(5):468-77.
Review Vaccines for preventing malaria. [Cochrane Database Syst Rev. 2003]
Review Vaccines for preventing malaria.
Graves P, Gelband H. Cochrane Database Syst Rev. 2003; (1):CD000129.
Review Antibodies and Plasmodium falciparum merozoites. [Trends Parasitol. 2001]
Review Antibodies and Plasmodium falciparum merozoites.
Ramasamy R, Ramasamy M, Yasawardena S. Trends Parasitol. 2001 Apr; 17(4):194-7.

See reviews... See all...

Cited by 2 PubMed Central articles

Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model. [Vaccine. 2011]
Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.
Cheng C, Pal S, Bettahi I, Oxford KL, Barry PA, de la Maza LM. Vaccine. 2011 Apr 18; 29(18):3456-64. Epub 2011 Mar 4.
Review Advances and challenges in malaria vaccine development. [J Clin Invest. 2010]
Review Advances and challenges in malaria vaccine development.
Crompton PD, Pierce SK, Miller LH. J Clin Invest. 2010 Dec; 120(12):4168-78. Epub 2010 Dec 1.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of m...
Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.
Vaccine. 2010 Sep 14 ;28(40):6573-80. Epub 2010 Aug 4 .

PubMed
First-year changes in blood lead and zinc protoporphyrin levels within two group...
First-year changes in blood lead and zinc protoporphyrin levels within two groups of occupational lead workers.
Am Ind Hyg Assoc J. 1991 Apr ;52(4):177-82.

PubMed
Generalized progressive retinal atrophy in the Irish Glen of Imaal Terrier is as...
Generalized progressive retinal atrophy in the Irish Glen of Imaal Terrier is associated with a deletion in the ADAM9 gene.
Mol Cell Probes. 2010 Dec ;24(6):357-63. Epub 2010 Aug 4 .

PubMed
Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral f...
Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets.
Br J Nutr. 2010 Dec ;104(11):1688-95. Epub 2010 Aug 9 .

PubMed
Chemical-genetic profile analysis of five inhibitory compounds in yeast.
Chemical-genetic profile analysis of five inhibitory compounds in yeast.
BMC Chem Biol. 2010 Aug 6 ;10:6.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Save items

Related citations in PubMed

Cited by 2 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information